NEWS
Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium
31.01.12
Protalix BioTherapeutics, announced today that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Networ ...more
31.01.12
Protalix BioTherapeutics, announced today that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Networ ...more
Genzyme Announces FDA Approval of Framingham Manufacturing Plant
26.01.12
Genzyme, a Sanofi company, announced today that the US Food and Drug Administration (FDA) has approved its manufacturing plant in Framingham, Mass., for the produ ...more
26.01.12
Genzyme, a Sanofi company, announced today that the US Food and Drug Administration (FDA) has approved its manufacturing plant in Framingham, Mass., for the produ ...more
FDA Extends taliglucerase alfa PDUFA Date to May 1, 2012
07.12.11
CARMIEL, Israel, December 6, 2011 Protalix BioTherapeutics, Inc. announced today that it received notification from the U.S. Food and Drug Administration (FDA) th ...more
07.12.11
CARMIEL, Israel, December 6, 2011 Protalix BioTherapeutics, Inc. announced today that it received notification from the U.S. Food and Drug Administration (FDA) th ...more
Protalix Announces Successful European GMP Audit
06.12.11
CARMIEL, Israel, Protalix BioTherapeutics, Inc. announced today that the Irish Medicines Board (IMB) has completed a successful GMP (Good Manufacturing Practice) ...more
06.12.11
CARMIEL, Israel, Protalix BioTherapeutics, Inc. announced today that the Irish Medicines Board (IMB) has completed a successful GMP (Good Manufacturing Practice) ...more
Gauchers Association moves into new offices
22.09.11
We are pleased to announce that as of the 12th September The Gauchers Association moved their office into new premises. Our new address is: Evesh ...more
22.09.11
We are pleased to announce that as of the 12th September The Gauchers Association moved their office into new premises. Our new address is: Evesh ...more
Protalix BioTherapeutics’ Taliglucerase Alfa Phase III Results Published in Blood, the Journal of the American Society of Hematology
12.09.11
CARMIEL, Israel, September 8, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), today announced that an article entitled "Pivotal Trial ...more
12.09.11
CARMIEL, Israel, September 8, 2011 /PR Newswire/Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), today announced that an article entitled "Pivotal Trial ...more
Protalix Submits Reply to FDA Complete Response Letter for Taliglucerase Alfa and Reports Top-Line Results from the Company's Switchover Trial
04.08.11
CARMIEL, Israel, Aug. 1, 2011 Protalix BioTherapeutics, Inc. (nyse-amex:PLX)(tase:PLX), announced today that it has submitted its reply to the Complete Resp ...more
04.08.11
CARMIEL, Israel, Aug. 1, 2011 Protalix BioTherapeutics, Inc. (nyse-amex:PLX)(tase:PLX), announced today that it has submitted its reply to the Complete Resp ...more
Gaucher's Cycle Ride
25.07.11
Gaucher’s Bike Ride London – Cambridge on Sunday 4th September 2011 Back by popular demand Start: University College School Playing Fields, Ranulf Road Lon ...more
25.07.11
Gaucher’s Bike Ride London – Cambridge on Sunday 4th September 2011 Back by popular demand Start: University College School Playing Fields, Ranulf Road Lon ...more
Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform
20.06.11
“RegistryNXT!” builds upon largest resource in the world for Gaucher disease data CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN ...more
20.06.11
“RegistryNXT!” builds upon largest resource in the world for Gaucher disease data CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN ...more
Shire launch new information website on Gaucher disease
27.05.11
This website has been developed for patients, carers and their families, it provides information on VPRIV the enzyme replacement therapy for Type I Gaucher diseas ...more
27.05.11
This website has been developed for patients, carers and their families, it provides information on VPRIV the enzyme replacement therapy for Type I Gaucher diseas ...more
The LSD Adult Service Birmingham - Launch Meeting
14.02.11
The Queen Elizabeth Hospital, part of University Hospitals Birmingham NHS Foundation Trust, would like to announce the launch of the Lysosomal Storage Disorders ( ...more
14.02.11
The Queen Elizabeth Hospital, part of University Hospitals Birmingham NHS Foundation Trust, would like to announce the launch of the Lysosomal Storage Disorders ( ...more
Protalix BioTherapeutics Presents Data on the Company's Fabry Program and Oral Enzyme Gaucher Program With Experts in the Field of Lysosomal Disorders
20.01.11
CARMIEL, Israel, Protalix BioTherapeutics, Inc. announced today that management presented data on the Company's preclinical Fabry program and oral enzym ...more
20.01.11
CARMIEL, Israel, Protalix BioTherapeutics, Inc. announced today that management presented data on the Company's preclinical Fabry program and oral enzym ...more
Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease
29.11.10
Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease New Yor ...more
29.11.10
Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease New Yor ...more
Head-to-Head Data Demonstrates Efficacy of VPRIV® (velaglucerase alfa for injection) Compared with Imiglucerase
08.11.10
Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease Head-to-Head Data Demons ...more
08.11.10
Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease Head-to-Head Data Demons ...more
Positive Data from taliglucerase alfa Switchover Trial
08.11.10
Protalix BioTherapeutics, Inc. announced positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, ...more
08.11.10
Protalix BioTherapeutics, Inc. announced positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, ...more
9th EWGGD Proceedings
21.10.10
Publication of the Proceedings of the 9th European Working Group on Gaucher Disease (EWGGD) The European Gaucher Alliance (EGA) has published the proceedings of ...more
21.10.10
Publication of the Proceedings of the 9th European Working Group on Gaucher Disease (EWGGD) The European Gaucher Alliance (EGA) has published the proceedings of ...more
European Commission Approval of VPRIV ( velaglucerase alfa)
29.08.10
Shire Announces European Approval of VPRIV® (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease Cambridge, ...more
29.08.10
Shire Announces European Approval of VPRIV® (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease Cambridge, ...more
Shire Receives CHMP Positive Opinion for VPRIV™
28.06.10
Shire Receives CHMP Positive Opinion for VPRIV™ (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union Shire plc (LSE: SHP, NAS ...more
28.06.10
Shire Receives CHMP Positive Opinion for VPRIV™ (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union Shire plc (LSE: SHP, NAS ...more
Cerezyme Emergency Treatment Program (CETP)
11.05.10
This program has been set up for the benefit of patients with type I and III Gaucher disease at high-risk for the development of progressive disease or complicati ...more
11.05.10
This program has been set up for the benefit of patients with type I and III Gaucher disease at high-risk for the development of progressive disease or complicati ...more
Product Supply Update
22.04.10
Cerezyme Genzyme achieved its goal of building a small inventory buffer during the first quarter. The current shipping allocation of 50 perce ...more
22.04.10
Cerezyme Genzyme achieved its goal of building a small inventory buffer during the first quarter. The current shipping allocation of 50 perce ...more
HG Shire Announces FDA Approval for Type 1 Gaucher Disease
02.03.10
HG Shire Announces FDA Approval of VPRIVTM (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease Click here to see full press release: Press Release
02.03.10
HG Shire Announces FDA Approval of VPRIVTM (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease Click here to see full press release: Press Release
Latest Cerezyme Update
17.02.10
Latest Cerezyme Update - 17th February 2010: Due to several factors including to improve manufacturing quality systems and perform preventative maintenance and ...more
17.02.10
Latest Cerezyme Update - 17th February 2010: Due to several factors including to improve manufacturing quality systems and perform preventative maintenance and ...more
Recommendations for treating patients with Gaucher disease with emerging enzyme products
15.01.10
A letter to the editor of the Blood Cells, Molecules and Diseases was published on the 18th December 2009 from Professor Timothy Cox, University of Cambridge Depa ...more
15.01.10
A letter to the editor of the Blood Cells, Molecules and Diseases was published on the 18th December 2009 from Professor Timothy Cox, University of Cambridge Depa ...more
European Medicines Agency's COMP Adopts Positive Opinion for the Orphan Drug Designation for Protalix's taliglucerase alfa
13.01.10
Press Release Source: Protalix BioTherapeutics, Inc. On Wednesday January 13, 2010, 7:30 am CARMIEL, Israel, Jan. 13 /PRNewswire/ -- Protali ...more
13.01.10
Press Release Source: Protalix BioTherapeutics, Inc. On Wednesday January 13, 2010, 7:30 am CARMIEL, Israel, Jan. 13 /PRNewswire/ -- Protali ...more
Guidelines for the restart of imiglucerase in patients with Gaucher disease: Recommendations from the European Working Group on Gaucher disease
07.01.10
Blood Cells, Molecules, and Diseases - 18th December 2009: Guidelines for the restart of imiglucerase in patients with Gaucher disease: Recommendations from the E ...more
07.01.10
Blood Cells, Molecules, and Diseases - 18th December 2009: Guidelines for the restart of imiglucerase in patients with Gaucher disease: Recommendations from the E ...more
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher Disease
09.12.09
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gauchers Disease CARMIEL, Israel--(BUSINESS WIRE)--Protalix Biotherapeutics, Inc. ...more
09.12.09
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gauchers Disease CARMIEL, Israel--(BUSINESS WIRE)--Protalix Biotherapeutics, Inc. ...more
Shire Submits European Marketing Authorization
25.11.09
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease Committee for Medicinal Produc ...more
25.11.09
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease Committee for Medicinal Produc ...more
Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease
07.10.09
Blood Cells, Molecules and Diseases. Based on the findings of the meeting of the EWGGD on Thursday 10th September in Bad Honnef, Germany, this paper includes ...more
07.10.09
Blood Cells, Molecules and Diseases. Based on the findings of the meeting of the EWGGD on Thursday 10th September in Bad Honnef, Germany, this paper includes ...more
Cerezyme Emergency Treatment Program
30.09.09
Dear Friends, I am writing to inform you of some very important developments in the management of the shortage of Cerezyme, which is so severely affecting Gauc ...more
30.09.09
Dear Friends, I am writing to inform you of some very important developments in the management of the shortage of Cerezyme, which is so severely affecting Gauc ...more
Cerezyme Supply Update
20.08.09
Dear Friends, I am writing to you, at what is a very difficult time for the global Gaucher community, to provide an update on the supply of Cerezyme and how the ...more
20.08.09
Dear Friends, I am writing to you, at what is a very difficult time for the global Gaucher community, to provide an update on the supply of Cerezyme and how the ...more
Shire files treatment protocol
09.07.09
Shire has filed a treatment protocol for velaglucerase alfa for Gaucher Disease Lexington, Massachusetts, US – July 6th, 2009 – Shire plc (LSE: SHP ...more
09.07.09
Shire has filed a treatment protocol for velaglucerase alfa for Gaucher Disease Lexington, Massachusetts, US – July 6th, 2009 – Shire plc (LSE: SHP ...more
Protalix Approached by the FDA
06.07.09
Protalix Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD in Patients with Gaucher Disease Allowing Expanded Access to prGCD ...more
06.07.09
Protalix Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD in Patients with Gaucher Disease Allowing Expanded Access to prGCD ...more
Cerezyme Supply
18.06.09
Genzyme Temporarily Interrupts Production at Allston Plant Genzyme announce temporary closure of Boston manufacturing plant : Read Genzyme press ...more
18.06.09
Genzyme Temporarily Interrupts Production at Allston Plant Genzyme announce temporary closure of Boston manufacturing plant : Read Genzyme press ...more
Small Grant for Type 2 Research
01.05.09
The Gauchers Association has awarded a small grant to The Royal Free Hospital, London to purchase a batch of viral vectors as part of their research in gene therapy in Type II Gaucher disease.
01.05.09
The Gauchers Association has awarded a small grant to The Royal Free Hospital, London to purchase a batch of viral vectors as part of their research in gene therapy in Type II Gaucher disease.
Protalix Switch over Trial
23.03.09
Protalix BioTherapeutics Announces First Patient Enrolled in Open-Label, Switchover Trial of prGCD for the Treatment of Gaucher Disease Protalix BioTherapeutics ...more
23.03.09
Protalix BioTherapeutics Announces First Patient Enrolled in Open-Label, Switchover Trial of prGCD for the Treatment of Gaucher Disease Protalix BioTherapeutics ...more
Addenbrookes Homecare
13.02.09
Addenbrookes is pleased to announce that it has awarded the contract for the provision of homecare for patients with Gaucher disease jointly to Careology an ...more
13.02.09
Addenbrookes is pleased to announce that it has awarded the contract for the provision of homecare for patients with Gaucher disease jointly to Careology an ...more
New Fundraising Packs
12.01.09
New fundraising packs – We are pleased to announce the availability of our brand-new fundraising packs. They are available free to all of our members and fr ...more
12.01.09
New fundraising packs – We are pleased to announce the availability of our brand-new fundraising packs. They are available free to all of our members and fr ...more
Recieve e-mail alerts.
12.01.09
Receive e-mail alerts – Sign up for regular news alerts delivered straight to your inbox. Click on the RSS link and as soon as the site is updated, you will receive an e-mail alert.
12.01.09
Receive e-mail alerts – Sign up for regular news alerts delivered straight to your inbox. Click on the RSS link and as soon as the site is updated, you will receive an e-mail alert.
New Gauchers News online
12.01.09
Gaucher News online – Our January 2009 newsletter is now available in three formats – hard copy, e-mail, or as a .pdf file. Choose your preferred opti ...more
12.01.09
Gaucher News online – Our January 2009 newsletter is now available in three formats – hard copy, e-mail, or as a .pdf file. Choose your preferred opti ...more